Spotlight on Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women with Disease Progression Following Antiestrogen Therapy

By Kate McKeage   Monique P. Curran   Greg L. Plosker  

American Journal of Cancer, Vol. 3, Iss. 4, 2004-01 ,pp. : 267-270

Adis International

Access to resources Recommend Favorite

Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial

By Kurosumi Masafumi   Takatsuka Yuichi   Watanabe Toru   Imoto Shigeru   Inaji Hideo   Tsuda Hitoshi   Akiyama Futoshi   Sakamoto Goi   Ikeda Tadashi   Noguchi Shinzaburo  

Journal of Cancer Research and Clinical Oncology, Vol. 134, Iss. 6, 2008-06 ,pp. : 715-722

Springer Publishing Company

Access to resources Recommend Favorite

The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer

By Beaver Julia A   Park Ben H  

Future Oncology, Vol. 8, Iss. 6, 2012-06 ,pp. : 651-657

Future Medicine

Access to resources Recommend Favorite

Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer

By Hayashi Naoki  

Breast Cancer Research and Treatment, Vol. 137, Iss. 2, 2013-01 ,pp. : 523-531

Springer Publishing Company

Access to resources Recommend Favorite

ERβ overexpression results in endocrine therapy resistance and poor prognosis in postmenopausal ERα-positive breast cancer patients

By          

Oncology Letters, Vol. 11, Iss. 2, 2016-01 ,pp. : 1531-1536

Spandidos Publications

Access to resources Recommend Favorite